This article is more than 5 years old. Information may no longer be current.
Imprimis reports significant reduction in CME post cataract surgery
Click Here to Manage Email Alerts
Investigators from Imprimis Pharmaceuticals announced positive clinical study results with its triamcinolone acetonide, moxifloxacin HCl and vancomycin Dropless Therapy formation in patients after cataract surgery at the American Society of Cataract and Refractive Surgery Congress.
The study prospectively compared rates of postoperative cystoid macular edema (CME) using traditional steroid and nonsteroidal anti-inflammatory drops (NSAIDs) with triamcinolone acetonide, moxifloxacin HCl and vancomycin dropless therapy (Tri-Moxi-Vanc) combined with an NSAID drop, in a total of 1,200 consecutive surgeries for 90 days of follow-up, according to a press release.
In the 600 patients in the historical group using NSAID and steroid drops postoperatively, the CME rate was 1.5%.
In another 600 patients receiving intravitreal Tri-Moxi-Vanc with postoperative NSAID drops, the CME rate was 0.5%, according to the release.
“The positive findings of this study... indicate a significant reduction in CME in postcataract surgery patients with our injectable Dropless Therapy (Tri-Moxi-Vanc) and an added NSAID topical eye drop compared to the group of patients treated with traditional individual NSAID and steroid topical drugs following [cataract] surgery,” according to Mark L. Baum, CEO, Imprimis, in the release.